We propose that DPYD testing should be evaluated through a globally transferable framework incorporating ancestry-aware variant coverage, rapid turnaround pathways, genotype-linked dose decision support, budget-impact assessment and real-world toxicity surveillance. Such an approach may help translate cost-effective pharmacogenomics into equitable, operationally feasible breast cancer care across diverse health systems.

The EXTREME regimen (platinum, 5-fluorouracil, and cetuximab) was the former first-line standard, but the advent of immune checkpoint inhibitors (ICIs), particularly pembrolizumab based on the KEYNOTE-048 trial, has transformed the treatment landscape. Economic evaluations show cost-effectiveness varies by region. Future directions include novel bispecific agents, triplet regimens, and biomarker-guided patient selection to optimize outcomes in this challenging disease.

P2, N=76, Recruiting, Sixth Affiliated Hospital, Sun Yat-sen University

Clinical courses were heterogeneous: one patient achieved a durable partial response using combined osimertinib and crizotinib. A second patient, intolerant to dual TKI therapy due to QTc prolongation and grade 3 edemas, achieved a sustained partial response with platinum-pemetrexed chemotherapy...However, its biological significance, driver versus passenger role, and therapeutic relevance remain uncertain. Combined EGFR and ROS1 inhibition may be considered in selected cases, but further validation is required.

Lower DPD and MTHFR expression predicts a favorable response to neoadjuvant CAPEOX in advanced CRC. These biomarkers offer a promising, non-invasive approach to personalizing treatment strategies potentially enhancing therapeutic efficacy while minimizing unnecessary toxicity.

P=N/A, N=480, Recruiting, Medical University of Gdansk

A 59-year-old man with CLDN18.2-positive stage IV gastric cancer and suspected peritoneal dissemination received zolbetuximab with capecitabine and oxaliplatin. This case suggests that zolbetuximab-based chemotherapy may enable conversion surgery in selected patients. Careful perioperative management is essential, and further studies are needed.

Serial CSF sampling also captured treatment-associated molecular shifts, including progressive TYMS amplification during intrathecal pemetrexed in an exploratory case. Together, these findings support low-input CSF sequencing as a practical molecular approach to complement LM diagnosis and longitudinal monitoring in lung cancer and provide a rationale for prospective validation in independent multi-center cohorts.

Circulating tumor DNA mutation status may serve as a prognostic biomarker in patients receiving HER2-targeted therapies. PIK3CA mutations were associated with worse outcomes, whereas ERBB2 mutations showed no significant effect. The prognostic significance of ctDNA was most pronounced in patients treated with TKIs, particularly pyrotinib, and remained evident in monotherapy and capecitabine-based regimens. These findings support the potential utility of ctDNA monitoring for risk stratification and personalized management in advanced HER2-positive breast cancer.

In the setting of second-line FOLFOX for ABC, elevated tumour markers impacted on prognosis and could be utilised as stratification factors in future clinical trials. The addition of FOLFOX did not imply QoL deterioration, and did, in fact, preserve some of the status in several domains.

Our research indicates that Quercetin serves as a promising EGFR-interacting compound and potential chemosensitizer, complementing conventional 5-FU therapy through enhanced receptor stabilization and modulation of EGFR-associated dynamics. Nonetheless, as the current results stem from molecular docking and MD simulations under optimal ligand-protein binding conditions, additional pharmacokinetic and experimental validation is required to ascertain whether physiologically attainable quercetin concentrations, given its established low bioavailability, can replicate these effects in vivo. These findings underscore the efficacy of bioinformatics-based methodologies in rational drug discovery and advocate for additional exploration of Quercetin-5-FU combinations for OSCC treatment.

She was started on fluorouracil, leucovorin, and oxaliplatin chemotherapy. Metastatic appendiceal carcinoma can closely resemble primary ovarian malignancy. Bilateral mucinous ovarian tumors with elevated CEA levels and poor chemotherapy response should prompt evaluation for a gastrointestinal primary tumor.